Irish biotechnology company Priothera Ltd revealed on Thursday the addition of Elisabeth Kueenburg, M.D. as its chief medical officer.

As head of the company's medical department, Dr Kueenburg will lead the advancement of mocravimod into Phase 2b/3 clinical trials in 2022 for Acute Myeloid Leukemia (AML) patients undergoing hematopoietic stem cell transplantation as well as oversee the expansion of its pipeline.

Most recently, Dr Kueenburg served as clinical development lead at Celgene, where she supported the successful global launch of Revlimid.

Previously, Dr Kueenburg spent more than 15 years in clinical practice and academic research specializing in oncology and hematology.